Viatris Is ‘Not Walking Away’ From Generics

Amid Steep Q1 Drop In Complex Generics, Company Reaffirms Commitment

 
• By Dave Wallace

After reporting sliding sales for both generics and complex generics in Q1, Viatris has nevertheless reaffirmed its commitment to the off-patent sector, highlighting in particular a planned launch this year of its Breyna rival to Symbicort.

Walking away in a desert, leaving footprints in the sand
After a mixed Q1, Viatris says it is not walking away from generics • Source: Shutterstock

More from Strategy

More from Business